Skip to main content
Journal cover image

Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.

Publication ,  Journal Article
Roser-Jones, C; Chan, M; Howard, EL; Becker, KCD; Rusconi, CP; Becker, RC
Published in: Cardiovascular therapeutics
August 2011

Anticoagulant therapy, combined with platelet-directed inhibitors, represents a standard-of-care in the management of patients with acute coronary syndrome, particularly those who require percutaneous coronary interventions. While a vast clinical experience, coupled with large clinical trials have collectively provided guidance, an optimal anticoagulant drug and applied strategy, defined as one that reduces thrombotic and hemorrhagic events consistently, with minimal off-target effects and active control of systemic anticoagulation according to patient and clinical-setting specific need, remains at large. An advancing knowledge of coagulation, hemostasis, and thrombosis suggests that factor IXa, a protease that governs thrombin generation in common thrombotic disorders may represent a prime target for pharmacologic inhibition.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cardiovascular therapeutics

DOI

EISSN

1755-5922

ISSN

1755-5914

Publication Date

August 2011

Volume

29

Issue

4

Start / End Page

e22 / e35

Related Subject Headings

  • Thrombosis
  • Protein Binding
  • Humans
  • Hemophilia B
  • Factor IXa
  • Cardiovascular System & Hematology
  • Blood Platelets
  • Binding Sites
  • Aptamers, Nucleotide
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Roser-Jones, C., Chan, M., Howard, E. L., Becker, K. C. D., Rusconi, C. P., & Becker, R. C. (2011). Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. Cardiovascular Therapeutics, 29(4), e22–e35. https://doi.org/10.1111/j.1755-5922.2010.00134.x
Roser-Jones, Christopher, Mark Chan, Emily L. Howard, Kristian C. D. Becker, Christopher P. Rusconi, and Richard C. Becker. “Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.Cardiovascular Therapeutics 29, no. 4 (August 2011): e22–35. https://doi.org/10.1111/j.1755-5922.2010.00134.x.
Roser-Jones C, Chan M, Howard EL, Becker KCD, Rusconi CP, Becker RC. Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. Cardiovascular therapeutics. 2011 Aug;29(4):e22–35.
Roser-Jones, Christopher, et al. “Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.Cardiovascular Therapeutics, vol. 29, no. 4, Aug. 2011, pp. e22–35. Epmc, doi:10.1111/j.1755-5922.2010.00134.x.
Roser-Jones C, Chan M, Howard EL, Becker KCD, Rusconi CP, Becker RC. Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. Cardiovascular therapeutics. 2011 Aug;29(4):e22–e35.
Journal cover image

Published In

Cardiovascular therapeutics

DOI

EISSN

1755-5922

ISSN

1755-5914

Publication Date

August 2011

Volume

29

Issue

4

Start / End Page

e22 / e35

Related Subject Headings

  • Thrombosis
  • Protein Binding
  • Humans
  • Hemophilia B
  • Factor IXa
  • Cardiovascular System & Hematology
  • Blood Platelets
  • Binding Sites
  • Aptamers, Nucleotide
  • Antibodies, Monoclonal